RU2017127772A - Человеческие антитела к токсинам clostridium difficile - Google Patents

Человеческие антитела к токсинам clostridium difficile Download PDF

Info

Publication number
RU2017127772A
RU2017127772A RU2017127772A RU2017127772A RU2017127772A RU 2017127772 A RU2017127772 A RU 2017127772A RU 2017127772 A RU2017127772 A RU 2017127772A RU 2017127772 A RU2017127772 A RU 2017127772A RU 2017127772 A RU2017127772 A RU 2017127772A
Authority
RU
Russia
Prior art keywords
clostridium difficile
patient
disease
condition
seq
Prior art date
Application number
RU2017127772A
Other languages
English (en)
Russian (ru)
Inventor
Аннэ ГУРНЕТТ-БАНДЕР
Карлос АРРЕКУБИЕТА
Исраель ЛОВИ
Original Assignee
Регенерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Регенерон Фармасьютикалз, Инк. filed Critical Регенерон Фармасьютикалз, Инк.
Publication of RU2017127772A publication Critical patent/RU2017127772A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
RU2017127772A 2012-03-02 2013-03-01 Человеческие антитела к токсинам clostridium difficile RU2017127772A (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261605914P 2012-03-02 2012-03-02
US61/605,914 2012-03-02
US201261608255P 2012-03-08 2012-03-08
US61/608,255 2012-03-08
US201261717404P 2012-10-23 2012-10-23
US61/717,404 2012-10-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014139552A Division RU2628305C2 (ru) 2012-03-02 2013-03-01 Человеческие антитела к токсинам clostridium difficile

Publications (1)

Publication Number Publication Date
RU2017127772A true RU2017127772A (ru) 2019-02-04

Family

ID=47844536

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017127772A RU2017127772A (ru) 2012-03-02 2013-03-01 Человеческие антитела к токсинам clostridium difficile
RU2014139552A RU2628305C2 (ru) 2012-03-02 2013-03-01 Человеческие антитела к токсинам clostridium difficile

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014139552A RU2628305C2 (ru) 2012-03-02 2013-03-01 Человеческие антитела к токсинам clostridium difficile

Country Status (18)

Country Link
US (2) US9399674B2 (enExample)
EP (1) EP2820044A1 (enExample)
JP (2) JP2015509962A (enExample)
KR (1) KR20140130709A (enExample)
CN (2) CN108101983A (enExample)
AR (1) AR090219A1 (enExample)
AU (1) AU2016203511A1 (enExample)
BR (1) BR112014021251A2 (enExample)
CA (1) CA2863536A1 (enExample)
HK (1) HK1200463A1 (enExample)
IL (1) IL233884A0 (enExample)
MX (1) MX2014010527A (enExample)
NZ (2) NZ714516A (enExample)
RU (2) RU2017127772A (enExample)
SG (2) SG11201405087PA (enExample)
TW (1) TWI592422B (enExample)
UY (1) UY34652A (enExample)
WO (1) WO2013130981A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9181632B1 (en) 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
US10533036B2 (en) 2015-02-19 2020-01-14 Immune Biosolutions Inc Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
CN107708729A (zh) * 2015-04-15 2018-02-16 免疫医疗公司 用于治疗艰难梭菌（clostridium difficile）感染和相关疾病的方法
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
WO2017189964A2 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN109912715A (zh) * 2017-12-13 2019-06-21 凯惠科技发展(上海)有限公司 一种EGFRvIII抗体及其偶联物、制备方法和应用
WO2020060771A1 (en) * 2018-09-18 2020-03-26 Vanderbilt University Human monoclonal antibodies to staphylococcal aureus isd proteins and uses thereof
US20200148762A1 (en) * 2018-11-09 2020-05-14 Avamab Pharma Inc. Methods for regulating endogenous production of antibodies against infectious diseases
CN111793130B (zh) * 2019-03-20 2021-09-14 华中农业大学 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
WO2021219786A1 (en) 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5224657A (en) 1989-05-23 1993-07-06 Kabushiki Kaisha Toshiba Cryogenic refrigerator
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
EP0822830B1 (en) * 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP1024826B1 (en) 1997-10-20 2005-03-16 Acambis, Inc. Passive immunization against clostridium difficile disease
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
CN1809591A (zh) * 2003-05-21 2006-07-26 米德列斯公司 针对炭疽芽孢杆菌保护性抗原的人单克隆抗体
EP2857418B1 (en) 2004-02-06 2017-07-26 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US20090107545A1 (en) 2006-10-09 2009-04-30 Soltaix, Inc. Template for pyramidal three-dimensional thin-film solar cell manufacturing and methods of use
EP1833510A4 (en) * 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
KR20080110908A (ko) * 2006-04-17 2008-12-19 쉐링-프라우 리미티드 재조합의 약독화된 클로스트리듐 유기체 및 백신
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
JP5345532B2 (ja) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Ｌｃｔ中毒に対する医薬品
US20110020356A1 (en) 2007-12-07 2011-01-27 Lin Fang Therapeutic clostridium difficile antibody compositions
AU2009219358A1 (en) 2008-02-28 2009-09-03 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
EP2405940B1 (en) 2009-02-20 2021-08-04 Secretary of State for Health and Social Care Antibodies to clostridium difficile toxins
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
JP2013505289A (ja) * 2009-09-23 2013-02-14 トーマス・ジュリアス・ボロディ 腸管感染症の治療法
WO2011063346A1 (en) 2009-11-20 2011-05-26 Northshore University Health System Research Institute Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
BR112012026021B1 (pt) 2010-04-15 2022-05-03 Progenics Pharmaceuticals, Inc Anticorpos, seus fragmentos de ligação ao antígeno e seus usos, composições e uso das mesmas, linhagem de células de hibridoma, kit, ácido nucleico, e vetor de expressão

Also Published As

Publication number Publication date
AR090219A1 (es) 2014-10-29
MX2014010527A (es) 2014-10-14
US20160264650A1 (en) 2016-09-15
KR20140130709A (ko) 2014-11-11
HK1200463A1 (en) 2015-08-07
AU2013203942A8 (en) 2016-08-11
NZ628943A (en) 2016-08-26
AU2013203942B2 (en) 2016-03-10
JP2015509962A (ja) 2015-04-02
CN108101983A (zh) 2018-06-01
CA2863536A1 (en) 2013-09-06
AU2016203511A1 (en) 2016-06-16
US9399674B2 (en) 2016-07-26
BR112014021251A2 (pt) 2017-06-27
AU2013203942A1 (en) 2013-09-19
IL233884A0 (en) 2014-09-30
NZ714516A (en) 2017-06-30
JP2018029625A (ja) 2018-03-01
TWI592422B (zh) 2017-07-21
EP2820044A1 (en) 2015-01-07
US20130230531A1 (en) 2013-09-05
SG11201405087PA (en) 2014-09-26
SG10201610123UA (en) 2017-01-27
CN104203976A (zh) 2014-12-10
TW201350501A (zh) 2013-12-16
RU2014139552A (ru) 2016-04-20
WO2013130981A1 (en) 2013-09-06
UY34652A (es) 2013-09-02
RU2628305C2 (ru) 2017-08-15

Similar Documents

Publication Publication Date Title
RU2014139552A (ru) Человеческие антитела к токсинам clostridium difficile
JP2015509962A5 (enExample)
US20220363750A1 (en) Arthritis treatment
JP2020536109A5 (enExample)
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
KR102296017B1 (ko) 혈관 질환 및 이에 따른 합병증 치료
RU2013142004A (ru) Конъюгаты "антитело-лекарственное средство"
RU2014138040A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
KR102104296B1 (ko) 종양성 질병들에 대한 치료
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
TW201902514A (zh) Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途
TW201623336A (zh) 抗免疫原性醣肽之抗體，包含彼等之組合物及其用途
RU2019104980A (ru) Анти-icos антитела
JP2020529469A5 (enExample)
ES2992409T3 (es) Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
WO2021052461A1 (zh) 抗α-溶血素的抗体及其应用
WO2023061472A1 (zh) 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
CN118922208A (zh) 用于消耗患病造血干细胞的组合物和方法
ES2539503T3 (es) Anticuerpos que se unen a TGF-alfa y Epiregulina
WO2024020236A2 (en) Monoclonal antibodies that interfere with iron uptake
WO2023143444A1 (zh) 抗dkk1抗体、其药物组合物及用途
CN119569867B (zh) 一种单克隆抗体及其在抗鲍曼不动杆菌感染中的应用
CN106632673A (zh) 抗pge2单克隆抗体及其使用

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20200804